Filtered By:
Drug: Pradaxa
Countries: Malaysia Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia
Conclusion Abrupt dabigatran discontinuation without an alternative oral anticoagulant increases the risk of thromboembolic events. As adverse drug events and renal impairment contribute substantially to the premature discontinuation of dabigatran, it is important to identify and monitor patients at risk to reduce dabigatran discontinuation rate especially during the first six months of dabigatran therapy.
Source: International Journal of Clinical Pharmacy - September 21, 2016 Category: Drugs & Pharmacology Source Type: research
